Addressing Unmet Needs with LP-284 for Relapsed/Refractory Lymphomas and Solid Tumors

Posted on by admin
1 min read

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing or emerging treatments for relapsed/refractory lymphomas and solid tumors.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours